Overall Management
~ Genetics of Breast & Ovarian Cancer

List was last updated on Oct 8, 2019 @ 7:32 pm.


    • Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
    • Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
    • JNCI Cancer Spectr. 2019 Oct 8; pkz075. doi: 10.1093/jncics/pkz075. eCollection 2019 Oct.

    Commentary:

    Preventing breast cancer in high risk women: is there still a role for oophorectomy?

    • All For BRCA, BRCA For All?
    • Resta R.
    • The DNA Exchange. 2019 Oct 7.
    • Preventing breast cancer in high risk women: is there still a role for oophorectomy?
    • Norquist BM, Swisher EM, Yung RL.
    • JNCI Cancer Spectr. 2019 Oct 4; pkz076. doi: 10.1093/jncics/pkz076. eCollection 2019 Jun.

    Original research:

    Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)

    • Mai PL, et al.
    • JNCI Cancer Spectr. 2019.
    • A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    • Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

    CME Audio Interview: Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer. (JN Learning : JAMA Oncology)

    Press: Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients. (GenomeWeb)

    • Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening Wider.
    • Robson M, Domchek S.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.4004. [Epub ahead of print]
    • Commentary
    • Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    • Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM.
    • Breast Cancer Res. 2019 Sep 18;21(1):107. doi: 10.1186/s13058-019-1193-1.
    • Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes.
    • Gao Y, Goldberg JE, Young TK, Babb JS, Moy L, Heller SL.
    • Radiology. 2019 Sep 17:190971. doi: 10.1148/radiol.2019190971. [Epub ahead of print]

    Press: Men at High Risk for Breast Cancer May Benefit From Screening. (Medscape Oncology)

    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.
    • Colin C, Doutriaux-Dumoulin I.
    • Radiology. 2019 Sep 3:191306. doi: 10.1148/radiol.2019191306. [Epub ahead of print]
    • Letter, Comment

    Original research:

    BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.

    • Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status.
    • Jeon HJ, Park HS, Park JS, Nam EJ, Lee ST, Han J.
    • Ann Surg Treat Res. 2019 Sep;97(3):113-118. doi: 10.4174/astr.2019.97.3.113. Epub 2019 Aug 29.
    • Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
    • Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK.
    • Obstet Gynecol. 2019 Sep;134(3):520-526. doi: 10.1097/AOG.0000000000003421.
    • An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    • Piccinin C, Panchal S, Watkins N, Kim RH.
    • Expert Rev Anticancer Ther. 2019 Aug 30. doi: 10.1080/14737140.2019.1659730. [Epub ahead of print]
    • Review
    • Pregnancy-associated breast cancer in a contemporary cohort of newly diagnosed women.
    • Gooch JC, Chun J, Kaplowitz E, Guth A, Axelrod D, Shapiro R, Roses D, Schnabel F.
    • Breast J. 2019 Aug 25. doi: 10.1111/tbj.13510. [Epub ahead of print]
    • Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk.
    • Moreno-Conde J, Alvarez-Romero C, Suárez-Mejías C, Martínez-Maestre MÁ, Silvan-Alfaro JM, Parra-Calderón CL.
    • Stud Health Technol Inform. 2019 Aug 21;264:704-708. doi: 10.3233/SHTI190314.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.
    • Walker M, Jacobson M, Sobel M.
    • CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    • Krassuski L, Vennedey V, Stock S, Kautz-Freimuth S.
    • BMC Med Inform Decis Mak. 2019 Aug 1;19(1):154. doi: 10.1186/s12911-019-0872-2.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
    • Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.
    • Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.
    • Combined hormonal contraceptives in BRCA gene mutation carriers: why not?
    • Grandi G, Sammarini M, Chiara Del Savio M, Toss A, Facchinetti F.
    • Eur J Contracept Reprod Health Care. 2019 Jul 30:1-3. doi: 10.1080/13625187.2019.1647335. [Epub ahead of print]
    • Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer.
    • Bercow AS, Eisenhauer EL.
    • J Surg Oncol. 2019 Jul 29. doi: 10.1002/jso.25645. [Epub ahead of print]
    • Review
    • Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    • Chang J, Seng S, Yoo J, Equivel P, Lum SS.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07595-2. [Epub ahead of print]
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    • Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D; KConFab Investigators; HEBON Investigators; GEMO Study Collaborators; EMBRACE Collaborators, Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D; CIMBA.
    • Br J Cancer. 2019 Jun 19. doi: 10.1038/s41416-019-0492-8. [Epub ahead of print]
    • BRCA2 deficiency is a potential driver for human primary ovarian insufficiency.
    • Miao Y, Wang P, Xie B, Yang M, Li S, Cui Z, Fan Y, Li M, Xiong B.
    • Cell Death Dis. 2019 Jun 17;10(7):474. doi: 10.1038/s41419-019-1720-0.
    • Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families.
    • Lakeman IMM, Hilbers FS, Rodríguez-Girondo M, Lee A, Vreeswijk MPG, Hollestelle A, Seynaeve C, Meijers-Heijboer H, Oosterwijk JC, Hoogerbrugge N, Olah E, Vasen HFA, van Asperen CJ, Devilee P.
    • J Med Genet. 2019 Jun 11. pii: jmedgenet-2019-106072. doi: 10.1136/jmedgenet-2019-106072. [Epub ahead of print]
    • A young woman's story of genetic testing and risk-reducing mastectomy.
    • [No author given]
    • FORCE. XRAYS. 2019 Jun 6.

    Narrative: I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer. (Health)

    • Breast Cancer Risk Prediction Models: Challenges in Clinical Application.
    • Paquin M, Fasolino T, Steck MB.
    • Clin J Oncol Nurs. 2019 Jun 1;23(3):256-259. doi: 10.1188/19.CJON.256-259.
    • Review
    • [Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.]
    • Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.
    • Trans-counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants.
    • Sacca RE, Koeller DR, Rana HQ, Garber JE, Morganstern DE.
    • J Genet Couns. 2019 Jun;28(3):708-716. doi: 10.1002/jgc4.1046. Epub 2019 Jan 24.
    • Hormone-based strategies for management of BrCa1 and 2 carriers.
    • Santen R.
    • Maturitas. 2019 Jun;124:120-121. doi: 10.1016/j.maturitas.2019.04.034.
    • Conference abstract, Review
    • Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
    • Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
    • Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
    • Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).
    • Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers TB, Doster JE, Zarwan C, Kruper L, Minasian L, Ford LG, Arun BK, Neuhouser ML, Goodman GE, Brown PH.
    • Cancer Prev Res (Phila). 2019 May 28. pii: canprevres.0444.2018. doi: 10.1158/1940-6207.CAPR-18-0444. [Epub ahead of print]
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • Breast cancer risk in BRCA1/2 mutation carriers and non-carriers under prospective intensified surveillance.
    • Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, Wappenschmidt B, Hübbel V, Maringa M, Reichstein-Gnielinski S, Hahnen E, Bartram CR, Dikow N, Schott S, Speiser D, Horn D, Fallenberg EM, Kiechle M, Quante AS, Vesper AS, Fehm T, Mundhenke C, Arnold N, Leinert E, Just W, Siebers-Renelt U, Weigel S, Gehrig A, Wöckel A, Schlegelberger B, Pertschy S, Kast K, Wimberger P, Briest S, Loeffler M, Bick U, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    • Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32396. [Epub ahead of print]
    • Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers.
    • George A.
    • Curr Genet Med Rep. 2019 May 9. doi: 10.1007/s40142-019-00167-6. [Epub ahead of print]
    • Review
    • Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer.
    • Giampaolino P, Della Corte L, Foreste V, Vitale SG, Chiofalo B, Cianci S, Zullo F, Bifulco G.
    • Minerva Med. 2019 May 6. doi: 10.23736/S0026-4806.19.06086-5. [Epub ahead of print]
    • Review
    • Hereditary ovarian cancers: state of the art.
    • Toss A, Molinaro E, Sammarini M, Del Savio MC, Cortesi L, Facchinetti F, Grandi G.
    • Minerva Med. 2019 May 6. doi: 10.23736/S0026-4806.19.06091-9. [Epub ahead of print]
    • Review
    • Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
    • Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.
    • Breast Cancer Res Treat. 2019 May;175(1):141-148. doi: 10.1007/s10549-018-05123-6. Epub 2019 Jan 23.
    • BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
    • Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E.
    • Radiology. 2019 Apr 30:181814. doi: 10.1148/radiol.2019181814. [Epub ahead of print]

    Letter, Comment:

    Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.

    • "A natural progression" - Australian women's attitudes about an individualised breast screening model.
    • Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE.
    • Cancer Prev Res (Phila). 2019 Apr 19. pii: canprevres.0443.2018. doi: 10.1158/1940-6207.CAPR-18-0443. [Epub ahead of print]
    • Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
    • Kehm RD, Hopper JL, John EM, Phillips KA, MacInnis RJ, Dite GS, Milne RL, Liao Y, Zeinomar N, Knight JA, Southey MC, Vahdat L, Kornhauser N, Cigler T, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, kConFab Investigators, Andrulis IL, Buys SS, Daly MB, Terry MB.
    • Breast Cancer Res. 2019 Apr 18;21(1):52. doi: 10.1186/s13058-019-1135-y.
    • Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.
    • Sandner AS, Weggel R, Mehraein Y, Schneider S, Hiddemann W, Spiekermann K.
    • PLoS One. 2019 Apr 18;14(4):e0215453. doi: 10.1371/journal.pone.0215453. eCollection 2019.
    • Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    • Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M.
    • Breast Cancer. 2019 Apr 12. doi: 10.1007/s12282-019-00971-6. [Epub ahead of print]
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

    Editorial:

    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

    • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
    • Deng H, Chen M, Guo X, Heng J, Xu X, Peng L, Jiang H, Li G, Day JX, Li J, Shan D, Li Y, Zhou Y, Liu B, Dai L, Wang X, Wang J.
    • Mol Genet Genomic Med. 2019 Apr 10:e672. doi: 10.1002/mgg3.672. [Epub ahead of print]
    • Predictive Power of PEN-3 Model Constructs in Breast Cancer Screening Behaviors among Teachers: A Cross- Sectional Study in Central Iran.
    • Moghaddam ES, Shahnazi H, Hassanzadeh A.
    • Eur J Breast Health. 2019 Apr 1;15(2):105-110. doi: 10.5152/ejbh.2019.4417. eCollection 2019 Apr.
    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Quick Uptakes: Taking the Uncertainty Out of Interpreting BRCA Variants.
    • Voelker R.
    • JAMA. 2019 Mar 20. doi: 10.1001/jama.2019.0967. [Epub ahead of print]

    Original research:

    BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.

    • Primary Care of Breast Cancer Survivors.
    • Zoberi K, Tucker J.
    • Am Fam Physician. 2019 Mar 15;99(6):370-375.
    • Review
    • Gaps in information about breast cancer risk and prevention impact African American women.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 14.

    Original research:

    Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.

    • Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    • Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, de Bock GH.
    • Breast. 2019 Mar 12;45:82-88. doi: 10.1016/j.breast.2019.03.004. [Epub ahead of print]
    • Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment.
    • Poortmans PMP, Kaidar-Person O.
    • Ann Oncol. 2019 Mar 1;30(3):348-350. doi: 10.1093/annonc/mdz014.
    • Research news, Editorial
    • Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
    • Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.
    • Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.

    Editorial:

    Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

    • Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".
    • Narod SA.
    • Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.
    • Letter, Reply

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Review:

    Personalised medicine and population health: breast and ovarian cancer.

    • Breast Cancer Screening: Why Can't Everyone Agree?
    • Jordan V, Khan M, Prill D.
    • Prim Care. 2019 Mar;46(1):97-115. doi: 10.1016/j.pop.2018.10.010. Epub 2018 Dec 22.
    • Review
    • Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses.
    • Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE, Grazioli L, Colagrande S, Giovagnoni A, Bellomi M; Italian Working Group on Magnetic Resonance.
    • Radiol Med. 2019 Mar;124(3):218-233. doi: 10.1007/s11547-018-0955-7. Epub 2018 Nov 14.
    • Review
    • The influence of BRCA variants of unknown significance on cancer risk management decision-making.
    • Chern JY, Lee SS, Frey MK, Lee J, Blank SV.
    • J Gynecol Oncol. 2019 Feb 27. doi: 10.3802/jgo.2019.30.e60. [Epub ahead of print]

    Editorial:

    Clinical significance of variants of unknown significances in BRCA genes.

    • Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    • Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K.
    • Eur J Health Econ. 2019 Feb 21. doi: 10.1007/s10198-019-01038-1. [Epub ahead of print]
    • Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    • Murthy P, Muggia F.
    • Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.
    • Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/2- carriers.
    • Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Floter Radestad A.
    • Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
    • Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    • Henry DA, Lee MC, Almanza D, Ahmed KA, Sun W, Boulware DC, Laronga C.
    • Breast Cancer Res Treat. 2019 Feb;174(1):39-45. doi: 10.1007/s10549-018-5057-7. Epub 2018 Nov 24.
    • Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
    • Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.
    • Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.
    • The impact of variant classification on the clinical management of hereditary cancer syndromes.
    • Turner SA, Rao SK, Morgan RH, Vnencak-Jones CL, Wiesner GL.
    • Genet Med. 2019 Feb;21(2):426-430. doi: 10.1038/s41436-018-0063-z. Epub 2018 Jun 6.
    • The Benefits and Blinders of Do-Goodism.
    • Resta R.
    • The DNA Exchange. 2019 Jan 20.
    • Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.
    • Jabaley T, Underhill-Blazey ML, Berry DL.
    • J Cancer Educ. 2019 Jan 19. doi: 10.1007/s13187-019-1470-9. [Epub ahead of print]
    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • The effects of genomic germline variant reclassification on clinical cancer care.
    • Slavin TP, Manjarrez S, Pritchard CC, Gray S, Weitzel JN.
    • Oncotarget. 2019 Jan 11;10(4):417-423. doi: 10.18632/oncotarget.26501. eCollection 2019 Jan 11.
    • Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.
    • Deli T, Orosz M, Jakab A.
    • Pathol Oncol Res. 2019 Jan 8. doi: 10.1007/s12253-018-00569-x. [Epub ahead of print]
    • Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
    • Sutherland S, Meiser B, Kaur R, Mitchell G, Kirk J, Peate M, Tim Wong WK, Goodwin A.
    • Breast J. 2019 Jan;25(1):34-40. doi: 10.1111/tbj.13157. Epub 2018 Dec 7.
    • Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    • Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.
    • Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.
    • Understanding and Practices of Gynaecologists Related to Breast Cancer Screening, Detection, Treatment and Common Breast Diseases: A Study from India.
    • Singh GN, Agarwal A, Jain V, Kumar P.
    • World J Surg. 2019 Jan;43(1):183-191. doi: 10.1007/s00268-018-4740-5.
    • Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    • Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R.
    • Ann Ital Chir. 2019;90:1-2.
    • Review
    • Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.
    • Padamsee TJ, Meadows R, Hils M.
    • Ethn Health. 2018 Dec 27:1-24. doi: 10.1080/13557858.2018.1562053. [Epub ahead of print]

    Research news: Gaps in information about breast cancer risk and prevention impact African American women (FORCE. XRAYS.)

    • BRCA Mutations and Breast Cancer Prevention.
    • Kotsopoulos J.
    • Cancers (Basel). 2018 Dec 19;10(12). pii: E524. doi: 10.3390/cancers10120524.
    • Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
    • Vargas E, Torres Lopez DM, de Deugd R, Gil F, Nova A, Mora L, Viaña LF, Hernandez JD, Bruges R, Hamann U.
    • Oncologist. 2018 Dec 12. pii: theoncologist.2018-0346. doi: 10.1634/theoncologist.2018-0346. [Epub ahead of print]
    • Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M.
    • Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP.
    • Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):173-177. doi: 10.1016/j.bbrc.2018.11.001. Epub 2018 Nov 8.

    Press: Novel Blood Test a Potential 'Game Changer' in Ovarian Cancer. (Medscape Oncology)

    • Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    • Doren A, Vecchiola A, Aguirre B, Villaseca P.
    • Climacteric. 2018 Dec;21(6):529-535. doi: 10.1080/13697137.2018.1514006. Epub 2018 Oct 8.
    • Review
    • Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
    • Vermeulen RFM, van Beurden M, Gaarenstroom KN, Teunis T, Kieffer JM, Aaronson NK, Kenter GG, Korse CM.
    • Climacteric. 2018 Dec;21(6):574-580. doi: 10.1080/13697137.2018.1512965. Epub 2018 Oct 8.
    • Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
    • D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.
    • Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.
    • [Additional non-contraceptive effects of contraception: CNGOF Contraception Guidelines].
    • Amat L, Bulach A, Leclercq M, Mesrine S, Scheffler F, Sperandeo D, Scheffler M.
    • Gynecol Obstet Fertil Senol. 2018 Dec;46(12):883-888. doi: 10.1016/j.gofs.2018.10.013. Epub 2018 Nov 7.
    • Review, [Article in French]
    • Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer.
    • Warner E.
    • Cancers (Basel). 2018 Nov 30;10(12). pii: E477. doi: 10.3390/cancers10120477.
    • Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation.
    • Ramos MCA, Folgueira MAAK, Maistro S, Campolina AG, Soárez PC, Bock GH, Novaes HMD, Diz MDPE.
    • Rev Saude Publica. 2018 Nov 29;52:94. doi: 10.11606/S1518-8787.2018052000643.
    • Cancer Risk-Reducing Opportunities in Gynecologic Surgery.
    • Piszczek C, Ma J, Gould CH, Tseng P.
    • J Minim Invasive Gynecol. 2018 Nov - Dec;25(7):1179-1193. doi: 10.1016/j.jmig.2017.10.025. Epub 2017 Oct 31.
    • Review
    • Cancer prevention and screening in a BRCA2-positive male to female transgender patient.
    • Li JZ, Tu HYV, Avram R, Pinthus J, Bordeleau L, Hodgson N.
    • Breast J. 2018 Nov;24(6):1112-1113. doi: 10.1111/tbj.13096. Epub 2018 Jul 23.
    • Commentary
    • Breast cancer screening in young women.
    • Desreux JAC.
    • Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:208-211. doi: 10.1016/j.ejogrb.2018.05.018. Epub 2018 May 24.
    • Review
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Cancer genetics program: Follow-up on clinical genetics and genomic medicine in Qatar.
    • Al-Bader SB, Alsulaiman R, Bugrein H, Ben Omran T, Abbaszadeh F, Bakheet N, Apsa Kusasi S, Abdou N, Solomon BD, Ghazouani H.
    • Mol Genet Genomic Med. 2018 Nov;6(6):865-872. doi: 10.1002/mgg3.534. Epub 2018 Dec 16.
    • Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    • van Nagell JR Jr, Burgess BT, Miller RW, Baldwin L, DeSimone CP, Ueland FR, Huang B, Chen Q, Kryscio RJ, Pavlik EJ.
    • Obstet Gynecol. 2018 Nov;132(5):1091-1100. doi: 10.1097/AOG.0000000000002921.

    Editorial, Research news:

    Ultrasound Screening for Ovarian Cancer: Are We There Yet?

    • Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.
    • Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balmaña J, Biancolella M, Bslok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R, Efremidis A, Fostira F, Goldgar D, Hadjisavvas A, Hansen TVO, Hirasawa A, Houdayer C, Kleiblova P, Krieger S, Lázaro C, Loizidou M, Manoukian S, Mensenkamp AR, Moghadasi S, Monteiro AN, Mori L, Morrow A, Naldi N, Nielsen HR, Olopade OI, Pachter NS, Palmero EI, Pedersen IS, Piane M, Puzzo M, Robson M, Rossing M, Sini MC, Solano A, Soukupova J, Tedaldi G, Teixeira M, Thomassen M, Tibiletti MG, Toland A, Törngren T, Vaccari E, Varesco L, Vega A, Wallis Y, Wappenschmidt B, Weitzel J, Spurdle AB, De Nicolo A, Gómez-García EB.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00091. Epub 2018 Oct 26.
    • Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.
    • Jatoi I.
    • Eur J Breast Health. 2018 Oct 1;14(4):189-193. doi: 10.5152/ejbh.2018.4324. eCollection 2018 Oct.
    • Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013.
    • Michaan N, Park SY, Won YJ, Lim MC.
    • Jpn J Clin Oncol. 2018 Oct 1;48(10):884-891. doi: 10.1093/jjco/hyy111.
    • Germline and somatic genetic testing in ovarian cancer patients.
    • Chandrasekaran D, Manchanda R.
    • BJOG. 2018 Oct;125(11):1460. doi: 10.1111/1471-0528.15225. Epub 2018 May 10.
    • Commentary
    • Breast cancer in transgender patients: A systematic review. Part 1: Male to female.
    • Hartley RL, Stone JP, Temple-Oberle C.
    • Eur J Surg Oncol. 2018 Oct;44(10):1455-1462. doi: 10.1016/j.ejso.2018.06.035. Epub 2018 Jul 25.
    • Review
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • Surgical prevention strategies in ovarian cancer.
    • Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS.
    • Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
    • Review
    • Personalised medicine and population health: breast and ovarian cancer.
    • Narod SA.
    • Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17.
    • Review

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Letter, Reply:

    Author response to “a response to ‘personalised medicine and population health: breast and ovarian cancer’”.

    • A Systematic Review of How Young People Live with Inherited Disease: What Can We Learn for Li-Fraumeni Syndrome?
    • Forbes Shepherd R, Lewis A, Keogh LA, Werner-Lin A, Delatycki MB, Forrest LE.
    • J Adolesc Young Adult Oncol. 2018 Oct;7(5):525-545. doi: 10.1089/jayao.2018.0028. Epub 2018 Jul 13.
    • Cancer experience in families affects decision making.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 25.

    Press: How a Loved One’s Experience With Cancer Guides Breast Cancer Decisions. (U.S. News & World Report)

    • Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance
    • Grubstein A, Rapson Y, Benzaquen O, Rozenblatt S, Gadiel I, Atar E, Yerushalmi R, Cohen MJ.
    • Clin Imaging. 2018 Sep - Oct;51:347-351. doi: 10.1016/j.clinimag.2018.06.010. Epub 2018 Jun 30.
    • Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
    • Amit A, Sabo E, Zohar Y, Trugman E, Pranovich I, Reiss A, Matanes E, Klorin G.
    • Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.
    • A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations.
    • Braun D, Yang J, Griffin M, Parmigiani G, Hughes KS.
    • J Genet Couns. 2018 Sep;27(5):1187-1199. doi: 10.1007/s10897-018-0238-4. Epub 2018 Mar 2.
    • Cancer genetics, precision prevention and a call to action.
    • Turnbull C, Sud A, Houlston RS
    • Nat Genet. 2018 Sep;50(9):1212-1218. doi: 10.1038/s41588-018-0202-0. Epub 2018 Aug 29.
    • Commentary

    Editorial:

    GPS for navigating healthcare.

    • Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy.
    • Zanna I, Silvestri V, Palli D, Magrini A, Rizzolo P, Saieva C, Zelli V, Bendinelli B, Vezzosi V, Valentini V, Bianchi S, Ottini L, Masala G.
    • Breast. 2018 Aug;40:85-91. doi: 10.1016/j.breast.2018.04.017. Epub 2018 Apr 28.
    • Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.
    • McVeigh TP, Wiggins J, Ward S, Kemp Z, George AJ.
    • Clin Breast Cancer. 2018 Aug;18(4):282-288. doi: 10.1016/j.clbc.2017.10.015. Epub 2017 Oct 28.
    • The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer.
    • Reinert T, Nogueira-Rodrigues A, Kestelman FP, Ashton-Prolla P, Graudenz MS, Bines J.
    • Clin Breast Cancer. 2018 Aug;18(4):e587-e594. doi: 10.1016/j.clbc.2018.03.006. Epub 2018 Mar 12.
    • Review
    • Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
    • Casey MJ, Salzman TA.
    • Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.
    • The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
    • Hesse-Biber S, Flynn B, Farrelly K.
    • Qual Health Res. 2018 Aug;28(10):1523-1538. doi: 10.1177/1049732318767395. Epub 2018 Apr 11.
    • Breast Cancer Genetics and Indications for Prophylactic Mastectomy.
    • Krontiras H, Farmer M, Whatley J.
    • Surg Clin North Am. 2018 Aug;98(4):677-685. doi: 10.1016/j.suc.2018.03.004. Epub 2018 May 30.
    • Review
    • DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).
    • Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW.
    • World J Oncol. 2018 Aug;9(4):119-122. doi: 10.14740/wjon1144w. Epub 2018 Sep 6.
    • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) — Genetic/Familial High-Risk Assessment: Breast and Ovarian
    • Daly MB, Pilarski R, Berry M, Buys SS, Friedman S, Garber JE, Hutton ML, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Laronga C, Litton JK, Madlensky L, Mac JS, Merajver SD, Offit K, Pal T, Peterson HJ, Reiser G, Shannon KM, Thaker P, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Darlow S.
    • NCCN.org. 2018 Jul 11. Version 1.2019.
    • Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers.
    • Honold F, Camus M.
    • Medwave. 2018 Jul 9;18(4):e7161. doi: 10.5867/medwave.2018.04.7160.
    • Review, Meta-Analysis, [Article in English, Spanish]
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.
    • Petelin L, Liew D, Mitchell G, James PA, Trainer AH.
    • Value Health. 2018 Jul;21(7):891-893. doi: 10.1016/j.jval.2018.02.009. Epub 2018 May 16.
    • Letter

    A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

    Letter:

    A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.

    • A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.
    • Li Y, Devlin JJ.
    • Value Health. 2018 Jul;21(7):893-894. doi: 10.1016/j.jval.2018.02.010. Epub 2018 Apr 5.
    • Letter

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Original Research:

    A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

    • Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort.
    • Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D.
    • JAMA Oncol. 2018 Jun 1;4(6):872-874. doi: 10.1001/jamaoncol.2018.0271.
    • Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
    • Lim KK, Yoon SY, Mohd Taib NA, Shabaruddin FH, Dahlui M, Woo YL, Thong MK, Teo SH, Chaiyakunapruk N.
    • Appl Health Econ Health Policy. 2018 Jun;16(3):395-406. doi: 10.1007/s40258-018-0384-8.
    • Personalized prevention in high risk individuals: Managing hormones and beyond.
    • Evans DG, Howell SJ, Howell A.
    • Breast. 2018 Jun;39:139-147. doi: 10.1016/j.breast.2018.03.009. Epub 2018 Mar 30.
    • Review
    • Recommendations on prevention and screening for breast cancer in Hong Kong.
    • Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R.
    • Hong Kong Med J. 2018 Jun;24(3):298-306. doi: 10.12809/hkmj177037.
    • Effects of Cancer Genetic Panel Testing on at-Risk Individuals.
    • Frost AS, Toaff M, Biagi T, Stark E, McHenry A, Kaltman R.
    • Obstet Gynecol. 2018 Jun;131(6):1103-1110. doi: 10.1097/AOG.0000000000002531.
    • Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    • Cheng H, Powers J, Schaffer K, Sartor O.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441.
    • Complex Medical Decision-Making for a Trans-Feminine Youth with a BRCA1 Mutation.
    • Wolf-Gould CS, Riley MR, Carswell JM.
    • LGBT Health. 2018 May/Jun;5(4):221-225. doi: 10.1089/lgbt.2017.0149.
    • Case report
    • A Trans-Feminine Youth with a BRCA1 Mutation: Case Study.
    • Wolf-Gould CS, Riley MR, Carswell JM.
    • LGBT Health. 2018 May/Jun;5(4):270-272. doi: 10.1089/lgbt.2017.0148. Epub 2018 May 11.
    • Letter, Case report
    • Ovarian Cancer Prevention and Screening.
    • Menon U, Karpinskyj C, Gentry-Maharaj A.
    • Obstet Gynecol. 2018 May;131(5):909-927. doi: 10.1097/AOG.0000000000002580.
    • Review
    • [Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17.
    • Consensus statement, Review, [Article in Spanish]
    • Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    • Patel S, Legood R, Evans DG, Turnbull C, Antoniou AC, Menon U, Jacobs I, Manchanda R.
    • Am J Obstet Gynecol. 2018 Apr;218(4):431.e1-431.e12. doi: 10.1016/j.ajog.2017.12.221. Epub 2017 Dec 26.
    • Commentary on changing the risk threshold for surgical prevention of ovarian cancer.
    • Manchanda R, Legood R, Antoniou AC, Pearce L, Menon U.
    • BJOG. 2018 Apr;125(5):541-544. doi: 10.1111/1471-0528.14763. Epub 2017 Jul 5.
    • Commentary
    • Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    • Liljegren A, von Wachenfeldt A, Azavedo E, Eloranta S, Grundström H, Ståhlbom AK, Sundbom A, Sundén P, Svane G, Ulitzsch D, Arver B.
    • Breast Cancer Res Treat. 2018 Apr;168(3):655-666. doi: 10.1007/s10549-017-4639-0. Epub 2018 Jan 9.
    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.
    • Scherr CL, Feuston JL, Nixon DM, Cohen SA.
    • J Genet Couns. 2018 Apr;27(2):439-445. doi: 10.1007/s10897-018-0222-z. Epub 2018 Feb 8.
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
    • Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ.
    • Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.
    • Review
    • [Cost-effectiveness of risk-reducing salpingo-oophorectomy in cases of BRCA1 gene mutation in Colombia].
    • González-Mariño MA.
    • Rev Salud Publica (Bogota). 2018 Mar-Apr;20(2):232-236. doi: 10.15446/rsap.V20n2.64866.
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16.
    • Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
    • Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.
    • Hereditary Cancers in Gynecology: What Physicians Should Know About Genetic Testing, Screening, and Risk Reduction.
    • Ring KL, Modesitt SC.
    • Obstet Gynecol Clin North Am. 2018 Mar;45(1):155-173. doi: 10.1016/j.ogc.2017.10.011.
    • Review
    • RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
    • Rao S, Cronin SJF, Sigl V, Penninger JM.
    • Trends Cell Biol. 2018 Mar;28(3):213-223. doi: 10.1016/j.tcb.2017.11.001. Epub 2017 Dec 11.
    • Review
    • A15 Blood cadmium (Cd) level as a marker of cancer risk in BRCA1 (+) prospective cohort study.
    • Marciniak W, Derkacz R, Baszuk P, Kuświk M, Kaczmarek K, Muszyńska M, Lener M, Huzarski T, Gronwald J, Oszurek O, Tołoczko-Grabarek A, Cybulski C, Dębniak T, Morawski A, Jakubowska A, Lubiński J.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A15. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • A16 Arsenic as a marker of cancer risk.
    • Derkacz R, Marciniak W, Baszuk P, Kuświk M, Kaczmarek K, Muszyńska M, Lener M, Huzarski T, Gronwald J, Oszurek O, Tołoczko-Grabarek A, Cybulski C, Dębniak T, Morawski A, Jakubowska A, Lubiński J.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A16. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW.
    • JAMA. 2018 Feb 13;319(6):588-594. doi: 10.1001/jama.2017.21926.

    Evidence Report, Review:

    Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

    Editorial: Screening for Ovarian Cancer in Asymptomatic Women (JAMA)

    Editorial: The Yet Unrealized Promise of Ovarian Cancer Screening (JAMA Oncology)

    Editorial: Is There a Future for Ovarian Cancer Screening? (JAMA Internal Medicine)

    JAMA Patient Page: Screening for Ovarian Cancer (JAMA)

    Press: 'No' to Ovarian Cancer Screening: Harms Outweigh Benefits. (Medscape)

    • Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Henderson JT, Webber EM, Sawaya GF.
    • JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421.

    Recommendation Statement:

    Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.

    Editorial: Screening for Ovarian Cancer in Asymptomatic Women (JAMA)

    Editorial: The Yet Unrealized Promise of Ovarian Cancer Screening (JAMA Oncology)

    Editorial: Is There a Future for Ovarian Cancer Screening? (JAMA Internal Medicine)

    JAMA Patient Page: Screening for Ovarian Cancer (JAMA)

    Press: 'No' to Ovarian Cancer Screening: Harms Outweigh Benefits. (Medscape)

    • Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
    • Saule C, Mouret-Fourme E, Briaux A, Becette V, Rouzier R, Houdayer C, Stoppa-Lyonnet D.
    • J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx159.
    • Changes in classification of genetic variants in BRCA1 and BRCA2.
    • Kast K, Wimberger P, Arnold N.
    • Arch Gynecol Obstet. 2018 Feb;297(2):279-280. doi: 10.1007/s00404-017-4631-2. Epub 2018 Jan 4.
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
    • Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG.
    • J Genet Couns. 2018 Feb;27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.
    • Men's information-seeking behavior regarding cancer risk and screening: A meta-narrative systematic review.
    • Saab MM, Reidy M, Hegarty J, O'Mahony M, Murphy M, Von Wagner C, Drummond FJ.
    • Psychooncology. 2018 Feb;27(2):410-419. doi: 10.1002/pon.4506. Epub 2017 Aug 18.
    • Review
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    • Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.
    • Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4.
    • A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting.
    • O'Leary MP, Goldner BS, Abboy S, Mercado PD, Plurad HY.
    • Fam Cancer. 2018 Jan;17(1):175-178. doi: 10.1007/s10689-017-0010-1.
    • BRCA mutations and reproduction.
    • Daum H, Peretz T, Laufer N.
    • Fertil Steril. 2018 Jan;109(1):33-38. doi: 10.1016/j.fertnstert.2017.12.004.
    • Review
    • The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
    • Moghadasi S, Meeks HD, Vreeswijk MP, Janssen LA, Borg Å, Ehrencrona H, Paulsson-Karlsson Y, Wappenschmidt B, Engel C, Gehrig A, Arnold N, Hansen TVO, Thomassen M, Jensen UB, Kruse TA, Ejlertsen B, Gerdes AM, Pedersen IS, Caputo SM, Couch F, Hallberg EJ, van den Ouweland AM, Collée MJ, Teugels E, Adank MA, van der Luijt RB, Mensenkamp AR, Oosterwijk JC, Blok MJ, Janin N, Claes KB, Tucker K, Viassolo V, Toland AE, Eccles DE, Devilee P, Van Asperen CJ, Spurdle AB, Goldgar DE, García EG.
    • J Med Genet. 2018 Jan;55(1):15-20. doi: 10.1136/jmedgenet-2017-104560. Epub 2017 May 10.
    • Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.
    • Powers B, Pal T, Laronga C.
    • Surg Oncol Clin N Am. 2018 Jan;27(1):1-22. doi: 10.1016/j.soc.2017.08.003.
    • Review
    • Multi-gene Panel Testing in Breast Cancer Management.
    • Fountzilas C, Kaklamani VG.
    • Cancer Treat Res. 2018;173:121-140. doi: 10.1007/978-3-319-70197-4_8.
    • Review
    • A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
    • Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D.
    • Int J Surg Case Rep. 2018;52:107-110. doi: 10.1016/j.ijscr.2018.10.014. Epub 2018 Oct 12.
    • The Preventive Intervention of Hereditary Breast Cancer.
    • Cao A, Huang L, Shao Z.
    • Adv Exp Med Biol. 2017 [2017 Dec 28];1026:41-57. doi: 10.1007/978-981-10-6020-5_3.
    • Review
    • Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    • Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeilinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.
    • PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017.
    • Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
    • Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, Halshtok O, Shalmon A, Gotlieb M, Friedman E.
    • Clin Breast Cancer. 2017 Dec 11. pii: S1526-8209(17)30559-1. doi: 10.1016/j.clbc.2017.12.005. [Epub ahead of print]
    • Prophylaxis of hereditary breast cancer.
    • de Groot JS, van Diest PJ, Derksen PWB.
    • Aging (Albany NY). 2017 Dec 8;9(12):2453-2454. doi: 10.18632/aging.101342.
    • Prophylactic Surgery: For Whom, When and How?
    • Mau C, Untch M.
    • Breast Care (Basel). 2017 Dec;12(6):379-384. doi: 10.1159/000485830. Epub 2017 Dec 13.
    • Prostate Cancer Screening in a New Era of Genetics.
    • Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.
    • Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31.
    • Review
    • Cost-effectiveness of Ovarian Cancer Prevention Strategies.
    • Kwon JS.
    • Clin Obstet Gynecol. 2017 Dec;60(4):780-788. doi: 10.1097/GRF.0000000000000317.
    • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.
    • Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M.
    • Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20.
    • Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    • Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA.
    • Gynecol Oncol. 2017 Dec;147(3):705-713. doi: 10.1016/j.ygyno.2017.10.001. Epub 2017 Oct 18.
    • Review
    • When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    • Speight B, Tischkowitz M.
    • J Genet Couns. 2017 Dec;26(6):1173-1178. doi: 10.1007/s10897-017-0136-1. Epub 2017 Aug 5.
    • Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
    • Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, Xholli A, Grandi G, Cagnacci A, Federico M.
    • Oncology. [2017 Dec;]93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.
    • Emerging Concepts in Gastric Neoplasia: Heritable Gastric Cancers and Polyposis Disorders.
    • van der Post RS, Carneiro F.
    • Surg Pathol Clin. 2017 Dec;10(4):931-945. doi: 10.1016/j.path.2017.07.011.
    • Review
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Current and future role of genetic screening in gynecologic malignancies.
    • Ring KL, Garcia C, Thomas MH, Modesitt SC.
    • Am J Obstet Gynecol. 2017 Nov;217(5):512-521. doi: 10.1016/j.ajog.2017.04.011. Epub 2017 Apr 12.
    • Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    • Hoskins PJ, Gotlieb WH.
    • CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
    • Screening for Recurrence and Secondary Cancers.
    • Simard JL, Kircher SM, Didwania A, Goel MS.
    • Med Clin North Am. 2017 Nov;101(6):1167-1180. doi: 10.1016/j.mcna.2017.06.010.
    • Review
    • Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
    • O'Quigley J.
    • Ann Epidemiol. 2017 Oct;27(10):672-676. doi: 10.1016/j.annepidem.2017.09.005. Epub 2017 Sep 20.
    • Review
    • Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
    • Wahner Hendrickson AE, Bakkum-Gamez JN, J Couch F, Ghosh K, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(11):3107-3109. doi: 10.1245/s10434-017-5999-8. Epub 2017 Jul 20.

    Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.

    • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    • Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA.
    • Ann Surg Oncol. 2017 Oct;24(11):3116-3123. doi: 10.1245/s10434-017-5995-z. Epub 2017 Jul 11.

    Editorial:

    Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.

    • [Entitlement to prophylactic treatment in cases of genetic predisposition for breast cancer : Interdisciplinary perspectives].
    • Meier F, Ried J, Harney A, Rhiem K, Neusser S, Neumann A, Wasem J, Schmutzler R, Huster S, Dabrock P.
    • Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Oct;60(10):1102-1108. doi: 10.1007/s00103-017-2608-8.
    • Review, [Article in German]
    • Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
    • Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    • Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.
    • Impact of germline and somatic BRCA1/2 mutations: Tumor spectrum and detection platforms.
    • Wu H, Wu X, Liang Z.
    • Gene Ther. 2017 Oct;24(10):601-609. doi: 10.1038/gt.2017.73. Epub 2017 Aug 3.
    • Review
    • Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    • Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R5, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.
    • JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.
    • Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries.
    • Pokharel HP, Hacker NF, Andrews L.
    • Hered Cancer Clin Pract. 2017 Sep 18;15:12. doi: 10.1186/s13053-017-0072-y. eCollection 2017.
    • Dynamic real-time in vivo confocal laser endomicroscopy of the fallopian tube during laparoscopy in the prevention of ovarian cancer.
    • Chene G, Chauvy L, Buenerd A, Moret S, Nadaud B, Chabert P, Lamblin G.
    • Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:18-23. doi: 10.1016/j.ejogrb.2017.07.002. Epub 2017 Jul 5.
    • The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    • Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, Gentry-Maharaj A, Kalsi JK, Singh N, Amso NN, Cruickshank D, Dobbs S, Godfrey K, Herod J, Leeson S, Mould T, Murdoch J, Oram D, Scott I, Seif MW, Williamson K, Woolas R, Fallowfield L, Campbell S, Skates SJ, Parmar M, Jacobs IJ.
    • Br J Cancer. 2017 Aug 22;117(5):619-627. doi: 10.1038/bjc.2017.222. Epub 2017 Jul 25.
    • ['Healthy sick' or: How Genetic Risks Lever the Disease Concept of the Healthcare System].
    • Meier F, Ried J, Braun M, Dabrock P.
    • Gesundheitswesen. 2017 Aug;79(8-09):594-598. doi: 10.1055/s-0043-109862. Epub 2017 Jul 14.
    • English Abstract, [Article in German]
    • BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
    • Neff RT, Senter L, Salani R.
    • Ther Adv Med Oncol. 2017 Aug;9(8):519-531. doi: 10.1177/1758834017714993. Epub 2017 Jun 19.
    • History, development and future of cancer screening in Australia.
    • Olver IN, Roder D.
    • Public Health Res Pract. 2017 Jul 26;27(3). pii: 2731725. doi: 10.17061/phrp2731725.
    • Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    • Skates SJ, Greene MH, Buys SS, Mai PL, Brown PH, Piedmonte M, Rodriguez GC, Schorge JO, Sherman M, Daly MB, Rutherford TJ, Brewster WR, O'Malley DM, Partridge EE, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek SM, Davidson SA, Edwards RP, Elg SA, Wakeley K, Phillips KA, Armstrong DK, Horowitz IR, Fabian CJ, Walker J, Sluss PM, Welch WR, Minasian L, Horick N, Kasten CH, Nayfield S, Alberts DS, Finkelstein DM, Lu K.
    • Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.
    • Risk Reduction Strategies in Breast Cancer Prevention.
    • Costa M, Saldanha P.
    • Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.
    • Inherited mutations in DNA repair genes and cancer risk.
    • Romero-Laorden N, Castro E.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):251-264. doi: 10.1016/j.currproblcancer.2017.02.009. Epub 2017 Mar 22.
    • Review
    • BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management.
    • Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO.
    • Radiographics. 2017 Jul-Aug;37(4):1005-1023. doi: 10.1148/rg.2017160144. Epub 2017 May 26.
    • Review
    • Managing hereditary breast cancer risk in women with and without ovarian cancer.
    • Peters ML, Garber JE, Tung N.
    • Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.
    • Review
    • Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
    • de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.
    • Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.
    • European/U.S. Comparison and Contrasts in Ovarian Cancer Screening and Prevention in a High-Risk Population.
    • Mourits MJ, de Bock GH.
    • Am Soc Clin Oncol Educ Book. [Presented Sunday, June 4, 2017.] 2017;37:124-127. doi: 10.14694/EDBK_180330.
    • BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.
    • Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calléja FMGR, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Brauch H, Brennan P, Brenner H, Broeks A, Brouwers B, Brüning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Cheng CY3, Choi JY, Collée JM, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Dörk T, Dos-Santos-Silva I, Dunning AM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hogervorst FB, Hollestelle A, Hopper JL, Ito H, Jakubowska A, Kang D, Kosma VM, Kristensen V, Lai KN, Lambrechts D, Marchand LL, Li J, Lindblom A, Lophatananon A, Lubinski J, Machackova E, Mannermaa A, Margolin S, Marme F, Matsuo K, Miao H, Michailidou K, Milne RL, Muir K, Neuhausen SL, Nevanlinna H, Olson JE, Olswold C, Oosterwijk JJC, Osorio A, Peterlongo P, Peto J, Pharoah PDP, Pylkäs K, Radice P, Rashid MU, Rhenius V, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schoemaker MJ, Seynaeve C, Shah M, Shen CY, Shrubsole M, Shu XO, Slager S, Southey MC, Stram DO, Swerdlow A, Teo SH, Tomlinson I, Torres D, Truong T, van Asperen CJ, van der Kolk LE, Wang Q, Winqvist R, Wu AH, Yu JC, Zheng W, Zheng Y, Leary J, Walker L, Foretova L, Fostira F, Claes KBM, Varesco L, Moghadasi S, Easton DF, Spurdle A, Devilee P, Vrieling H, Monteiro ANA, Goldgar DE, Carreira A, Vreeswijk MPG, Couch FJ; for kConFab/AOCS Investigators; for NBCS Collaborators.
    • Cancer Res. 2017 Jun 1;77(11):2789-2799. doi: 10.1158/0008-5472.CAN-16-2568. Epub 2017 Mar 10.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.
    • Pérez-López FR, Ceausu I, Depypere H, Kehoe S, Lambrinoudaki I, Mueck A, Senturk LM, Simoncini T, Stevenson JC, Stute P, Rees M.
    • Maturitas. 2017 Jun;100:86-91. doi: 10.1016/j.maturitas.2017.03.003. Epub 2017 Mar 15.
    • Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.
    • Digennaro M, Sambiasi D, Tommasi S, Pilato B, Diotaiuti S, Kardhashi A, Trojano G, Tufaro A, Paradiso AV.
    • Hered Cancer Clin Pract. 2017 May 25;15:7. doi: 10.1186/s13053-017-0067-8. eCollection 2017.
    • 5 Big Questions (and Answers) on Inherited Prostate Cancer Testing.
    • Nick Mulcahy
    • Medscape. Coverage from the American Urological Association (AUA) 2017 Annual Meeting. 2017 May 18.
    • Is There a Role for Ovarian Cancer Screening in High-Risk Women?
    • Berchuck A, Havrilesky LJ, Kauff ND.
    • J Clin Oncol. 2017 May 1;35(13):1384-1386. doi: 10.1200/JCO.2016.72.0045. Epub 2017 Mar 6.

    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.

    • Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    • Rosenthal AN, Fraser LS, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, Evans DG, Eccles DM, Ryan A, Liston R, Dawnay A, Ford J, Gunu R, Mackay J, Skates SJ, Menon U, Jacobs IJ; United Kingdom Familial Ovarian Cancer Screening Study collaborators.
    • J Clin Oncol. 2017 May 1;35(13):1411-1420. doi: 10.1200/JCO.2016.69.9330. Epub 2017 Feb 27.

    Editorial:

    Is There a Role for Ovarian Cancer Screening in High-Risk Women?

    • Imaging of Hereditary Tumors of the Female Genital System.
    • Rothan SM, Menias CO, ElGuindy YM, Jensen CT, Shaaban A, Bhosale P, Lee MV, Katabathina VS, Elsayes KM.
    • J Comput Assist Tomogr. 2017 May/Jun;41(3):364-375. doi: 10.1097/RCT.0000000000000558.
    • Review
    • Chronic Pancreatitis-Like Change in BRCA2 Mutation Carriers.
    • Mizrahi M, Tseng JF, Wong D, Tung N, Eskander MF, Berzin TM, Pleskow DK, Sawhney MS.
    • Pancreas. 2017 May/Jun;46(5):679-683. doi: 10.1097/MPA.0000000000000814.
    • European/U.S. Comparison and Contrasts in Ovarian Cancer Screening and Prevention in a High-Risk Population.
    • Mourits MJ, de Bock GH.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):124-127. doi: 10.1200/EDBK_180330.
    • Hereditary Ovarian Cancer and Risk Reduction.
    • Andrews L, Mutch DG.
    • Best Pract Res Clin Obstet Gynaecol. 2017 May;41:31-48. doi: 10.1016/j.bpobgyn.2016.10.017. Epub 2017 Jan 17.
    • Review
    • The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.
    • Afghahi A, Kurian AW.
    • Curr Treat Options Oncol. 2017 May;18(5):27. doi: 10.1007/s11864-017-0468-y.
    • Review
    • Transvaginal laparoscopy: A minimally invasive approach to obtain brush cytology of the Fallopian tube.
    • Gordts S, Campo R, Bogers JP, Tanos V, Segaert I, Valkenburg M, Puttemans P, Gordts S.
    • Eur J Obstet Gynecol Reprod Biol. 2017 May;212:80-84. doi: 10.1016/j.ejogrb.2017.03.002. Epub 2017 Mar 12.
    • Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    • McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
    • Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
    • Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.
    • Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525.
    • The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    • Fallowfield L, Solis-Trapala I, Menon U, Langridge C, May S, Jacobs I, Jenkins V.
    • Br J Cancer. 2017 Apr 11;116(8):1111-1117. doi: 10.1038/bjc.2017.72. Epub 2017 Mar 21.
    • Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Breast. 2017 Apr;32:186-191. doi: 10.1016/j.breast.2017.02.008. Epub 2017 Feb 17.
    • Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
    • El Bairi K, Kandhro AH, Gouri A, Mahfoud W, Louanjli N, Saadani B, Afqir S, Amrani M.
    • Cell Oncol (Dordr). 2017 Apr;40(2):105-118. doi: 10.1007/s13402-016-0309-1. Epub 2016 Dec 15.
    • Review
    • Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    • Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.
    • Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.
    • A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    • Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ.
    • Value Health. 2017 Apr;20(4):547-555. doi: 10.1016/j.jval.2017.01.006. Epub 2017 Feb 23.

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Letter:

    A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.

    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    • Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.
    • Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • A brother and sister with breast cancer, BRCA2 mutations and bilateral supernumerary nipples.
    • McKay M, Coad R.
    • Ann Transl Med. 2017 Mar;5(5):106. doi: 10.21037/atm.2017.03.02.
    • Identification, genetic testing, and management of hereditary melanoma.
    • Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P.
    • Cancer Metastasis Rev. 2017 Mar;36(1):77-90. doi: 10.1007/s10555-017-9661-5.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer.
    • Al-Moghrabi NM.
    • J Taibah Univ Med Sci. 2017 Feb 22;12(3):189-193. doi: 10.1016/j.jtumed.2017.01.004. eCollection 2017 Jun.
    • DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
    • Wu HC, Southey MC, Hibshoosh H, Santella RM, Terry MB.
    • Anticancer Res. 2017 Feb;37(2):659-664.
    • BRCA mutation genetic testing implications in the United States.
    • Bayraktar S, Arun B.
    • Breast. 2017 Feb;31:224-232. doi: 10.1016/j.breast.2016.11.021. Epub 2016 Dec 6.
    • [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
    • Kida K, Murai M, Yamauchi H.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):111-115.
    • Review, [Article in Japanese]
    • [Clinical Management of HBOC in Our Hospital].
    • Nomura H, Takeshima N.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):116-120.
    • [Article in Japanese]
    • A novel hysteroscopic approach for ovarian cancer screening/early diagnosis.
    • Gizzo S, Noventa M, Quaranta M, Vitagliano A, Saccardi C, Litta P, Antona D.
    • Oncol Lett. 2017 Feb;13(2):549-553. doi: 10.3892/ol.2016.5493. Epub 2016 Dec 14.
    • Commentary: Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers.
    • Glassey R, Saunders C, Hardcastle SJ.
    • Front Psychol. 2017 Jan 31;8:121. doi: 10.3389/fpsyg.2017.00121. eCollection 2017.

    Review:

    Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers

    • Breast Cancer Epidemiology, Prevention, and Screening.
    • Winters S, Martin C, Murphy D, Shokar NK.
    • Prog Mol Biol Transl Sci. 2017;151:1-32. doi: 10.1016/bs.pmbts.2017.07.002. Epub 2017 Oct 10.
    • Review
    • Male transgender breast cancer patient shares his experience in NYT piece.
    • Lisa Rezende, Julie Huynh
    • FORCE. XRAYS. 2016 Dec 21.
    • Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    • Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE.
    • Breast Cancer Res Treat. 2016 Dec;160(3):393-410. Epub 2016 Oct 12.
    • Review
    • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
    • Weinberger V, Bednarikova M, Cibula D, Zikan M.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1311-1321. Epub 2016 Oct 22.
    • Review
    • Prevention of breast cancer.
    • Olver IN.
    • Med J Aust. 2016 Nov 21;205(10):475-479.
    • Review
    • The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    • Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.
    • Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.
    • Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.
    • Zahavi T, Yahav G, Shimshon Y, Gershanov S, Kaduri L, Sonneblick A, Fixler D, Salmon AY, Salmon-Divon M.
    • Biochem Biophys Res Commun. 2016 Nov 4;480(1):36-41. doi: 10.1016/j.bbrc.2016.10.013. Epub 2016 Oct 6.
    • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
    • Larouche G, Chiquette J, Plante M, Pelletier S, Simard J, Dorval M.
    • Can Assoc Radiol J. 2016 Nov;67(4):308-312. doi: 10.1016/j.carj.2015.12.003. Epub 2016 Jun 16.
    • Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.
    • Chudecka-Głaz A, Cymbaluk-Płoska A, Luterek-Puszyńska K, Menkiszak J.
    • Oncol Lett. 2016 Nov;12(5):3101-3114. Epub 2016 Aug 29.
    • Prevention and Screening in Hereditary Breast and Ovarian Cancer.
    • Zeichner SB, Stanislaw C, Meisel JL.
    • Oncology (Williston Park). 2016 Oct 15;30(10). pii: 219285.

    Commentary

    Clinical Hereditary Cancer Syndromes and Gene Panel Testing.

    • Identification and management of women with a family history of breast cancer: Practical guide for clinicians.
    • Heisey R, Carroll JC.
    • Can Fam Physician. 2016 Oct;62(10):799-803.
    • Management of women with a hereditary predisposition for breast cancer.
    • Jatoi I, Benson JR.
    • Future Oncol. 2016 Oct;12(19):2277-88. doi: 10.2217/fon-2016-0186. Epub 2016 Jul 7.
    • Review
    • Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer.
    • Cobain EF, Milliron KJ, Merajver SD.
    • Semin Oncol. 2016 Oct;43(5):528-535. doi: 10.1053/j.seminoncol.2016.10.001. Epub 2016 Oct 8.
    • Review
    • Genetic predisposition in gynecologic cancers.
    • Daniels MS, Lu KH.
    • Semin Oncol. 2016 Oct;43(5):543-547. doi: 10.1053/j.seminoncol.2016.08.005. Epub 2016 Sep 20.
    • Review
    • FDA Updates Recommendation Against Ovarian Cancer Screening.
    • [No author given]
    • My Gene Counsel. 2016 Sep 16.
    • The biological effects and clinical implications of BRCA mutations: where do we go from here?
    • Stoppa-Lyonnet D.
    • Eur J Hum Genet. 2016 Sep;24 Suppl 1:S3-9. doi: 10.1038/ejhg.2016.93.
    • A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
    • Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.
    • Isr Med Assoc J. 2016 Sep;18(9):549-552.

    Editorial:

    Handling Individuals with High Cancer Risk: One Size Doesn't Fit All.

    • Hereditary breast and ovarian cancer: new genes in confined pathways.
    • Nielsen FC, van Overeem Hansen T, Sørensen CS.
    • Nat Rev Cancer. 2016 Sep;16(9):599-612. doi: 10.1038/nrc.2016.72. Epub 2016 Aug 12.
    • Review
    • Counselling framework for moderate-penetrance cancer-susceptibility mutations.
    • Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME.
    • Nat Rev Clin Oncol. 2016 Sep;13(9):581-8. doi: 10.1038/nrclinonc.2016.90. Epub 2016 Jun 14.
    • Review
    • RE: BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
    • Arbustini E, Sgarella A, Ferrari A, Grasso D, Cassani C, Lucioni M, Di Giulio G, Grasso M.
    • J Natl Cancer Inst. 2016 Aug 31;108(12). pii: djw172. doi: 10.1093/jnci/djw172. Print 2016 Dec.
    • Letter

    Letter, Reply

    Response.

    • Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    • Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
    • EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.
    • Multidisciplinary team for elucidation of any new mutation and how this approach can be useful to individualize any genetic result: the case of BRCA2 c.631G>A/c.7008-2A>T genotype Response to: Nagy PL, Mansukhani M. The role of clinical genomic testing in diagnosis and discovery of pathogenic mutations. Expert Rev Mol Diagn 2015;15(9):1101-5.
    • Minucci A, De Bonis M, Costella A, Scambia G, Scandurra G, Capoluongo E.
    • Expert Rev Mol Diagn. 2016 Jul;16(7):715-7. doi: 10.1080/14737159.2016.1184573. Epub 2016 May 17.

    Editorial

    The role of clinical genomic testing in diagnosis and discovery of pathogenic mutations.

    • Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer.
    • Lai T, Kessel B, Ahn HJ, Terada KY.
    • J Gynecol Oncol. 2016 Jul;27(4):e41. doi: 10.3802/jgo.2016.27.e41. Epub 2016 Apr 6.
    • The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening.
    • Smits S, Boivin J, Menon U, Brain K.
    • Ecancermedicalscience. 2016 Jun 30;10:650. doi: 10.3332/ecancer.2016.650. eCollection 2016.
    • An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
    • Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E.
    • Breast Cancer Res Treat. 2016 Jun;157(2):319-27. doi: 10.1007/s10549-016-3805-0. Epub 2016 Apr 27.
    • Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.
    • Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S.
    • Front Oncol. 2016 May 11;6:119. doi: 10.3389/fonc.2016.00119. eCollection 2016.
    • Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    • Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.
    • Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.
    • Women's Health Issues for BRCA Mutation Carriers.
    • Sabatini ME, Ellisen LW.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):14-17. doi: 10.1200/EDBK_100001.
    • Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
    • Lan Z, Fu D, Yu X, Xi M.
    • Fam Cancer. 2016 Apr;15(2):221-30. doi: 10.1007/s10689-015-9847-3.
    • Meta-Analysis, Review
    • Genetics of triple-negative breast cancer: Implications for patient care.
    • Afghahi A, Telli ML, Kurian AW.
    • Curr Probl Cancer. 2016 Mar - Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23.
    • Review
    • Managing patients at genetic risk of breast cancer.
    • Pederson HJ, Padia SA, May M, Grobmyer S.
    • Cleve Clin J Med. 2016 Mar;83(3):199-206. doi: 10.3949/ccjm.83a.14057.
    • Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.
    • Hall MJ, Obeid EI, Schwartz , Mantia-Smaldone G, Forman AD, Daly MB.
    • Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019. Epub 2016 Jan 23.
    • Review
    • Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".
    • Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii.
    • Letter

    Case report

    Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

    Response / Letter

    The Authors Respond.

    • Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.
    • Ruddy KJ, Risendal BC, Garber JE, Partridge AH.
    • J Clin Oncol. 2016 Feb 20;34(6):539-41. doi: 10.1200/JCO.2015.63.5375. Epub 2015 Dec 28.
    • Beyond BRCA: Testing negative and living in the 'gray zone' for cancer risk.
    • [No author given]
    • My Gene Counsel. 2016 Feb 16.
    • Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    • Lin PH, Kuo WH, Huang AC, Lu YS, Lin CH, Kuo SH, Wang MY, Liu CY, Cheng FT, Yeh MH, Li HY, Yang YH, Hsu YH, Fan SC, Li LY, Yu SL, Chang KJ, Chen PL, Ni YH, Huang CS.
    • Oncotarget. 2016 Feb 16;7(7):8310-20. doi: 10.18632/oncotarget.7027.
    • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    • Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S.
    • J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: NCCN High-Risk Breast-Ovarian Guidelines 1.2016

    • Women's Health Issues for BRCA Mutation Carriers.
    • Sabatini ME, Ellisen LW.
    • Am Soc Clin Oncol Educ Book. 2016;35:14-17. doi: 10.14694/EDBK_100001.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: hormonal birth control with ATM mutations?

    • Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information.
    • Kurian AW, Antoniou AC, Domchek SM.
    • Am Soc Clin Oncol Educ Book. 2016;35:44-56. doi: 10.14694/EDBK_158817.
    • Ovarian cancer test rolled out across five US states.
    • Kate Sweeney.
    • Business Weekly. BioMedTech. 2015 Dec 2.
    • [Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers].
    • Zikán M.
    • Klin Onkol. 2015 Winter;29 Suppl 1:22-30.
    • Review, [Article in Czech]
    • How medical choices influence quality of life of women carrying a BRCA mutation.
    • Harmsen MG, Hermens RP, Prins JB, Hoogerbrugge N, de Hullu JA.
    • Crit Rev Oncol Hematol. 2015 Dec;96(3):555-68. doi: 10.1016/j.critrevonc.2015.07.010. Epub 2015 Jul 26.
    • Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.
    • Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, Helbich TH.
    • Wien Klin Wochenschr. 2015 Dec;127(23-24):981-6. doi: 10.1007/s00508-015-0880-x. Epub 2015 Nov 2.
    • Risk factors and biomarkers of life-threatening cancers.
    • Autier P.
    • Ecancermedicalscience. 2015 Nov 24;9:596. doi: 10.3332/ecancer.2015.596. eCollection 2015.
    • Genetics: Relative risk.
    • Velasquez-Manoff M.
    • Nature. 2015 Nov 18;527(7578):S116-S117. doi: 10.1038/527S116a.
    • Review
    • Management of breast cancer in very young women.
    • Rosenberg SM, Partridge AH.
    • Breast. 2015 Nov;24 Suppl 2:S154-8. doi: 10.1016/j.breast.2015.07.036.
    • Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
    • Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li C, Anderson GL.
    • Gynecol Oncol. 2015 Nov;139(2):253-260. doi: 10.1016/j.ygyno.2015.08.024. Epub 2015 Sep 3.
    • Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    • Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D, Ross TS.
    • EBioMedicine. 2015 Oct 21;2(11):1827-33. doi: 10.1016/j.ebiom.2015.10.022. eCollection 2015.

    Commentary

    Differences in Uptake of Risk Reduction Strategies Among Underserved Populations.

    • Recommendations and Reality: What Personal Stories of Hereditary Cancer Can Tell Us.
    • Ridgely Fisk Green, Katrina Trivers.
    • CDC. Genomics and Health Impact Blog. 2015 Jun 1.
    • Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    • Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW.
    • JAMA Oncol. 2015 Oct 1;1(7):943-951. doi: 10.1001/jamaoncol.2015.2690.

    Comment

    Usefulness of Multigene Testing: Catching the Train That's Left the Station.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Article Requestp

    Press: Multigene Panel Test Finds Mutations in BRCA-Negative Individuals. (Medscape Oncology)

    Press: Testing for more breast cancer genes offers useful information. (Reuters Health)

    Press: Monitoring Techniques for Hereditary Breast and Ovarian Cancer Being Developed. (Targeted Oncology)

    • Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations.
    • Katz SJ, Kurian AW, Morrow M.
    • JAMA. 2015 Sep 8;314(10):997-998. doi: 10.1001/jama.2015.8088.
    • Editorial / Commentary
    • Physician Risk Assessment Knowledge Regarding BRCA Genetics Testing.
    • Cohn J, Blazey W, Tegay D, Harper B, Koehler S, Laurent B, Chan V, Jung MK, Krishnamachari B.
    • J Cancer Educ. 2015 Sep;30(3):573-9. doi: 10.1007/s13187-014-0724-9.
    • Genetic Testing Can Lead to Insights — Or Uncertainty.
    • Lauren M. Green.
    • Cure. 2015 Aug 13.
    • Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.
    • Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK.
    • Cancer. 2015 Jul 1;121(13):2108-20. doi: 10.1002/cncr.29321. Epub 2015 Mar 27.

    Commentary

    Ovarian cancer prevention: Time for primetime?

    • Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.
    • Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):835-45.
    • Breast Cancer Risk Reduction, Version 2.2015.
    • Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.
    • Practice guideline
    • Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    • Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I.
    • J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.

    News

    CA-125 blood test in early detection of ovarian cancer.

    Comment / News

    Change in blood protein detects more ovarian cancers than fixed threshold, study finds.

    Comment

    Gynaecological cancer: Biomarker potential of CA-125 enhanced.

    Comment / Letter

    Preventing Ovarian Cancer.

    Comment / Letter

    Definition of Specificity in a Screening Trial.

    Comment / Letter

    Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al.

    Comment / Letter

    Ovarian Cancer Early Detection Needs Better Imaging, Not Better Algorithms or Biomarkers.

    Press: New ovarian cancer test twice as accurate. (Care Appointments)

    Press: Personalised screening revives cancer biomarker hope. (PHG Foundation)

    Press: New Screening Method May Identify More Ovarian Cancers. (Medscape / Reuters Health)

    Press: More Ovarian Cancer Detected if Biomarker Velocities Are Scrutinized. (Clinical OMICs)

    • Personalization of loco-regional care for primary breast cancer patients (part 2).
    • Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.
    • Future Oncol. 2015 May;11(9):1301-5. doi: 10.2217/fon.15.66.
    • An integrated breast cancer risk assessment and management model based on fuzzy cognitive maps.
    • Subramanian J, Karmegam A, Papageorgiou E, Papandrianos N, Vasukie A.
    • Comput Methods Programs Biomed. 2015 Mar;118(3):280-97. doi: 10.1016/j.cmpb.2015.01.001. Epub 2015 Jan 21.
    • Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    • Saam J, Moyes K, Landon M, Williams K, Kaldate RR, Arnell C, Wenstrup R.
    • Oncology. [2015 Mar;]88(4):226-33. doi: 10.1159/000368836. Epub 2014 Dec 11.
    • Personalized assessment and management of women at risk for breast cancer in North America.
    • Pruthi S, Heisey R, Bevers T.
    • Womens Health (Lond Engl). 2015 Mar;11(2):213-23; quiz 223-4. doi: 10.2217/whe.14.79.
    • Breast cancer risks and risk prediction models.
    • Engel C, Fischer C.
    • Breast Care (Basel). 2015 Feb;10(1):7-12. doi: 10.1159/000376600.
    • Clinical management of women at high risk of breast cancer.
    • Wuttke M, Phillips KA.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):6-13. doi: 10.1097/GCO.0000000000000140.
    • Review
    • Clinical management of patients at inherited risk for gynecologic cancer.
    • Powell CB.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):14-22. doi: 10.1097/GCO.0000000000000143.
    • Review
    • American BRCA Outcomes and Utilization of Testing (ABOUT) Study: A Pragmatic Research Model that Incorporates Personalized Medicine/Patient-Centered Outcomes in a Real World Setting.
    • Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE, Casares C, Teten RT, Kondoff MR, Molina AD, Abdollahian M, Brand L, Walker GS, Sutphen R.
    • J Genet Couns. 2015 Feb;24(1):18-28. doi: 10.1007/s10897-014-9750-3. Epub 2014 Sep 12.
    • A survey of genetic counselors about the needs of 18-25 year olds from families with hereditary breast and ovarian cancer syndrome.
    • Werner-Lin A, Ratner R, Hoskins LM, Lieber C.
    • J Genet Couns. 2015 Feb;24(1):78-87. doi: 10.1007/s10897-014-9739-y. Epub 2014 Jul 12.
    • A comprehensive approach to the identification and management of the BRCA patient.
    • Garcia C, Powell CB.
    • Obstet Gynecol Surv. 2015 Feb;70(2):131-43. doi: 10.1097/OGX.0000000000000156.
    • Review
    • Breast cancer prevention.
    • Euhus DM, Diaz J.
    • Breast J. 2015 Jan-Feb;21(1):76-81. doi: 10.1111/tbj.12352. Epub 2014 Nov 20.
    • [Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: Literature review.]
    • Jégu M, Der AS, Morcel K, Abadie C, Fritel X, Levêque J.
    • J Gynecol Obstet Biol Reprod (Paris). 2015 Jan;44(1):10-17. doi: 10.1016/j.jgyn.2014.10.011. Epub 2014 Nov 18.
    • Review, [Article in French]
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Comment / Introductory Journal Article

    Preface.

    • Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers.
    • Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.
    • JAMA Surg. 2014 Dec 1;149(12):1306-1313. doi: 10.1001/jamasurg.2014.1081.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    Letter

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers.

    Letter, Reply

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers-Reply.

    • [The importance of screening in oncogynecology].
    • Frühauf F, Sláma J, Zikán M.
    • Ceska Gynekol. 2014 Dec;79(6):491-8.
    • Review, [Article in Czech]
    • Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.
    • Ohman AW, Hasan N, Dinulescu DM.
    • Front Oncol. 2014 Nov 18;4:322. doi: 10.3389/fonc.2014.00322. eCollection 2014.
    • The role of genome sequencing in personalized breast cancer prevention.
    • Sieh W, Rothstein JH, McGuire V, Whittemore AS.
    • Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2322-7. doi: 10.1158/1055-9965.EPI-14-0559.

    Press: Genomic Sequencing More Efficient in Predicting Breast Cancer Risk Than Previously Thought. (AACR Newsroom)

    Blog: Cancer Genomics: Using Big Data to Advance Breast Cancer Risk Prediction. (Cancer Research Catalyst/AACR)

    Press: Here’s How Well Your Genes Can Predict Your Breast Cancer Risk. (Time | Health)

    • Screening and Nonsurgical Methods of Prevention for Women at High Risk for Breast Cancer.
    • Victoria Seewaldt
    • FORCE. Be Empowered Webinars. 2014 Oct 22.
    • BRCA and Men: Medical Management and Prostate-specific Considerations.
    • Jacquelyn Powers.
    • FORCE. Be Empowered Webinars. 2014 Oct 1.
    • Management of young breast cancer patients with de novo genetic mutations.
    • Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF.
    • Oncology (Williston Park). 2014 Oct;28(10):895-6.
    • Risk determination and prevention of breast cancer.
    • Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN.
    • Breast Cancer Res. 2014 Sep 28;16(5):446. doi: 10.1186/s13058-014-0446-2.
    • Genetic/Familial high-risk assessment: breast and ovarian, version 1.2014.
    • Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R.
    • J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.
    • Practice Guideline, NCCN Guidelines
    • Biology of breast cancer in young women.
    • Azim HA, Partridge AH.
    • Breast Cancer Res. 2014 Aug 27;16(4):427. doi: 10.1186/s13058-014-0427-5.
    • The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review.
    • Roeke T, van Bommel AC, Gaillard-Hemmink MP, Hartgrink HH, Mesker WE, Tollenaar RA.
    • Breast Cancer Res Treat. 2014 Aug;147(1):15-23. doi: 10.1007/s10549-014-3074-8. Epub 2014 Aug 8.
    • Review
    • Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women.
    • Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N.
    • Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1.
    • Personalized therapy for breast cancer.
    • De Abreu FB, Schwartz GN, Wells WA, Tsongalis GJ.
    • Clin Genet. 2014 Jul;86(1):62-7. doi: 10.1111/cge.12381. Epub 2014 Apr 9.
    • An update on breast cancer screening and prevention.
    • de la Cruz MS, Sarfaty M, Wender RC.
    • Prim Care. 2014 Jun;41(2):283-306. doi: 10.1016/j.pop.2014.02.006. Epub 2014 Mar 27.
    • Review
    • [Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers].
    • Synowiec A, Wcisło G, Bodnar L, Gasowska-Bodnar A, Szczylik C.
    • Ginekol Pol. 2014 May;85(5):377-81.
    • Review, [Article in Polish]
    • Tools of the trade: individualized breast cancer risk assessment.
    • Millstine D, David P, Pruthi S.
    • J Womens Health (Larchmt). 2014 May;23(5):434-6. doi: 10.1089/jwh.2014.4761. Epub 2014 Apr 7.
    • Management of women at high risk of breast cancer.
    • Armstrong AC, Evans GD.
    • BMJ. 2014 Apr 28;348:g2756. doi: 10.1136/bmj.g2756.
    • Review
    • Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.
    • Kotsopoulos J, Metcalfe K, Alston J, Nikitina D, Ginsburg O, Eisen A, Demsky R, Akbari M, Zbuk K, Narod SA.
    • BMC Cancer. 2014 Mar 25;14:221. doi: 10.1186/1471-2407-14-221.
    • [Risk-adapted surveillance: focus on familial breast and ovarian cancer].
    • Rhiem K, Schmutzler RK.
    • Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Mar;57(3):307-11. doi: 10.1007/s00103-013-1910-3.
    • [Article in German]
    • In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.
    • Hoskins LM, Werner-Lin A, Greene MH.
    • PLoS One. 2014 Feb 28;9(2):e87696. doi: 10.1371/journal.pone.0087696. eCollection 2014.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
    • Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.
    • Ann Intern Med. 2014 Feb 18;160(4):255-66.
    • Assessing the Genetic Risk for BRCA-Related Breast or Ovarian Cancer in Women: Recommendations From the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4). doi: 10.7326/P14-9008.

    Systematic Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2014 Feb 18;160(4):271-81.

    Patient Education Handout:

    Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.

    • Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4):I-16.

    Practice Guideline:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.

    • Ovarian cancer screening-Current status, future directions.
    • Menon U, Griffin M, Gentry-Maharaj A.
    • Gynecol Oncol. 2014 Feb;132(2):490-495. doi: 10.1016/j.ygyno.2013.11.030. Epub 2013 Dec 3.
    • How to spot heritable breast cancer: a primary care physician's guide.
    • Smith M, Mester J, Eng C.
    • Cleve Clin J Med. 2014 Jan;81(1):31-40. doi: 10.3949/ccjm.81a.13051.
    • The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
    • Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti M.
    • Clin Genet. 2014 Jan;85(1):7-15. doi: 10.1111/cge.12298. Epub 2013 Nov 5.
    • Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Kim-Sing C, Ghadirian P, Sun P, Narod S.
    • Clin Genet. 2014 Jan;85(1):21-30. doi: 10.1111/cge.12233. Epub 2013 Aug 26.
    • Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States.
    • Cragun D, Pal T.
    • ISRN Oncol. 2013 Dec 22;2013:260847. doi: 10.1155/2013/260847. eCollection 2013.
    • Ask Well: Genetic Testing for Breast Cancer.
    • Roni Caryn Rabin.
    • New York Times. Ask Well. 2013 Nov 27.
    • Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    • Collins IM, Milne RL, Weideman PC, McLachlan SA, Friedlander ML, Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer KC, Hopper JL, Phillips KA.
    • Med J Aust. 2013 Nov 18;199(10):680-3.
    • Oophorectomy can reduce ovarian cancer risk in women with BRCA mutations: Patients benefit from counseling, support.
    • Printz C.
    • Cancer. 2013 Nov 15;119(22):3897-8. doi: 10.1002/cncr.28455.
    • The role of the fallopian tube in the origin of ovarian cancer.
    • Erickson BK, Conner MG, Landen CN Jr.
    • Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.

    Letter, Comment:

    Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.

    Letter, Reply:

    Reply: To PMID 23583217.

    • Alternatives to risk-reducing surgery for ovarian cancer.
    • Gadducci A, Sergiampietri C, Tana R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311.
    • Local approaches to hereditary breast cancer.
    • Cooper BT, Murphy JO, Sacchini V, Formenti SC.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii54-viii60. doi: 10.1093/annonc/mdt327.
    • A qualitative study of women's experiences of familial ovarian cancer screening.
    • Lifford KJ, Clements A, Fraser L, Lancastle D, Brain K; PsyFOCS Management Group.
    • Psychooncology. 2013 Nov;22(11):2576-84. doi: 10.1002/pon.3324. Epub 2013 Jun 26.
    • A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
    • Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr.
    • Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183. Epub 2013 Aug 26.

    Press: Ovarian cancer screening 'has potential'. (BBC)

    Press: Prospects for ovarian cancer screening. (PHG Foundation)

    • Breast fine-needle aspiration cytology performance in the high-risk screening population: A study of BRCA1/BRCA2 mutation carriers.
    • Georgieva RD, Obdeijn IM, Jager A, Hooning MJ, Tilanus-Linthorst MM, van Deurzen CH.
    • Cancer Cytopathol. 2013 Oct;121(10):561-7. doi: 10.1002/cncy.21308. Epub 2013 May 29.
    • Patterns of breast cancer surveillance and breast cancer detection in women with serous ovarian/tubal or peritoneal carcinomas who have had brca mutation testing.
    • Daniel Paik, Farin Amersi, Alexandra Gangi, Catherine Dang, Beth Karlan, Ronald Leuchter, Andrew Li, Christine Walsh, B.J. Rimel, Ilana Cass.
    • Gynecologic Oncology. 2013 Oct;131(1):264. doi: 10.1016/j.ygyno.2013.07.046.
    • Conference abstract
    • Challenging and complex decisions in the management of the BRCA mutation carrier.
    • Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.
    • J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29.
    • Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis.
    • Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L.
    • Gynecol Oncol. 2013 Sep;130(3):674-81. doi: 10.1016/j.ygyno.2013.06.029. Epub 2013 Jun 30.
    • Meta-Analysis, Review
    • Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
    • Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collée JM, Seynaeve C, Hooning MJ.
    • Ann Oncol. 2013 Aug;24(8):2029-35. doi: 10.1093/annonc/mdt134. Epub 2013 Apr 10.
    • Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    • Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.
    • BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.
    • Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
    • Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, Ghadirian P, Sun P, Narod S; Hereditary Breast Cancer Study Group.
    • Clin Genet. 2013 Jul;84(1):43-6. doi: 10.1111/cge.12037. Epub 2012 Nov 7.
    • A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
    • Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, Shen K, Kong B.
    • Gynecol Oncol. 2013 Jul;130(1):132-9. doi: 10.1016/j.ygyno.2013.04.048. Epub 2013 Apr 25.
    • Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
    • Tilanus-Linthorst MM, Lingsma HF, Evans DG, Thompson D, Kaas R, Manders P, van Asperen CJ, Adank M, Hooning MJ, Kwan Lim GE, Eeles R, Oosterwijk JC, Leach MO, Steyerberg EW.
    • Int J Cancer. 2013 Jul;133(1):156-63. doi: 10.1002/ijc.28014. Epub 2013 Feb 13.
    • Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.
    • Wu YY, Yen MF, Yu CP, Chen HH.
    • Br J Cancer. 2013 Jun 11;108(11):2241-9. doi: 10.1038/bjc.2013.202. Epub 2013 May 14.
    • A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.
    • de Bruin MA, Ford JM, Kurian AW.
    • J Natl Compr Canc Netw. 2013 May 1;11(5):512-7.
    • Genetic predisposition syndromes and their management.
    • Euhus DM, Robinson L.
    • Surg Clin North Am. 2013 Apr;93(2):341-62. doi: 10.1016/j.suc.2013.01.005. Epub 2013 Feb 11.
    • Review
    • Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening.
    • Katapodi MC, Northouse LL, Schafenacker AM, Duquette D, Duffy SA, Ronis DL, Anderson B, Janz NK, McLosky J, Milliron KJ, Merajver SD, Duong LM, Copeland G.
    • BMC Cancer. 2013 Mar 1;13:97. doi: 10.1186/1471-2407-13-97.
    • Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
    • Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW.
    • Fam Cancer. 2013 Mar;12(1):65-73. doi: 10.1007/s10689-012-9577-8.
    • Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
    • Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, Peock S, Stoppa-Lyonnet D; KConFab Investigators, Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MG; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, Brenner H, Lochmann M; GENICA Network, Aittomäki K, Dörk T, Margolin S, Mannermaa A, Lambrechts D, Chang-Claude J, Radice P, Giles GG, Haiman CA, Winqvist R, Devillee P, García-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PD, Jakubowska A, Orr N, González-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, Altshuler D, Easton DF, Chenevix-Trench G, Antoniou AC, Offit K.
    • PLoS Genet. 2013 Mar;9(3):e1003173. doi: 10.1371/journal.pgen.1003173. Epub 2013 Mar 27.
    • Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
    • Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA.
    • PLoS Genet. 2013 Mar;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.
    • Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
    • Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS.
    • JAMA Intern Med. 2013 Jan 28;173(2):96-103. doi: 10.1001/2013.jamainternmed.962.

    Comment:

    Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".

    • Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".
    • Grann V, Ashby-Thompson M.
    • JAMA Intern Med. 2013 Jan 28;173(2):103-4. doi: 10.1001/jamainternmed.2013.2729.

    Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

    • Ovarian cancer: in search of better marker systems based on DNA repair defects.
    • Varga D, Deniz M, Schwentner L, Wiesmüller L.
    • Int J Mol Sci. 2013 Jan 4;14(1):640-73. doi: 10.3390/ijms14010640.
    • Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
    • Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ.
    • J Clin Oncol. 2013 Jan 1;31(1):49-57. doi: 10.1200/JCO.2011.39.7638. Epub 2012 Dec 3.

    Editorial:

    Screening for familial ovarian cancer: a ray of hope and a light to steer by.

    • Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers.
    • Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.
    • Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

    Editorial/Comment:

    Ideal Risk Reduction Management for Women With BRCA Gene Mutations: Still Not There Yet.

    • Evaluation of breast self-examination (BSE) application in first and second degree relatives of patients with breast cancer.
    • Bebis H, Altunkurek SZ, Acikel C, Akar I, Altunkurek SZ.
    • Asian Pac J Cancer Prev. 2013;14(8):4925-30.
    • [Choices for women at risk of hereditary breast cancer].
    • Saadatmand S, Obdeijn IM, Koppert LB, Tilanus-Linthorst M.
    • Ned Tijdschr Geneeskd. 2013;157(43):A6625.
    • Case report, Review, [Article in Dutch]
    • Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2012 Dec 18;157(12):900-4. doi: 10.7326/0003-4819-157-11-201212040-00539.

    Summary for patients:

    Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.

    Study Synopsis and Perspective, CME: Who Should Be Screened for Ovarian Cancer? (Medscape Education Clinical Briefs)

    • Ovarian cancer molecular pathology.
    • Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, Day R, Fournier I, Salzet M.
    • Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32. doi: 10.1007/s10555-012-9383-7.
    • Review
    • Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer.
    • Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.
    • Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7.
    • [Diagnostics of breast cancer in high-risk women - our own experience].
    • Palácová M, Krásenská M, Ondračková A, Petráková K, Schneiderová M, Foretová L, Navrátilová M, Hanousková D.
    • Klin Onkol. [2012 Aug;]25 Suppl:S96-8.
    • Pregnancy and Fertility for Previvors and Survivors.
    • Jennifer Litton.
    • FORCE. Be Empowered Webinars. 2012 Jun 19.
    • Managing the breast in patients who test positive for hereditary breast cancer.
    • Euhus D.
    • Ann Surg Oncol. 2012 Jun;19(6):1738-44. doi: 10.1245/s10434-012-2258-x. Epub 2012 Mar 7.
    • Review
    • French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing.
    • Maheu C, Apostolidis T, Petri-Cal A, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Noguès C, Julian-Reynier C.
    • Fam Cancer. 2012 Jun;11(2):269-78. doi: 10.1007/s10689-012-9512-z.
    • The potential for risk stratification in the management of ovarian cancer risk.
    • Pharoah PD.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S16-7. doi: 10.1097/IGC.0b013e318251caaf.
    • Review
    • BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
    • Crum CP, McKeon FD, Xian W.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34. doi: 10.1097/IGC.0b013e31824d7269.
    • Screening for gynaecologic cancers in genetically predisposed women.
    • Dreyer G.
    • Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):267-82. doi: 10.1016/j.bpobgyn.2011.11.002. Epub 2012 Feb 22.
    • Review
    • Prevention of breast cancer in the context of a national breast screening programme.
    • Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans DG.
    • J Intern Med. 2012 Apr;271(4):321-30. doi: 10.1111/j.1365-2796.2012.02525.x.
    • Update on the IMPACT Study and Implications for Men with BRCA Mutations.
    • Jacquelyn Powers.
    • FORCE. Be Empowered Webinars. 2012 Mar 27.
    • A surveillance conundrum: a case of 4 distinct primary malignancies in a BRCA-1 mutation carrier.
    • Ricci S, Shafer A, Nerenstone S, Mandavilli S, Sorosky J.
    • Int J Gynecol Pathol. 2012 Mar;31(2):145-8. doi: 10.1097/PGP.0b013e318227ad58.
    • Case Report
    • Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    • Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S; for the DOvE Study Group.
    • Lancet Oncol. 2012 Mar;13(3):285-91. doi: 10.1016/S1470-2045(11)70333-3. Epub 2012 Jan 17.
    • High-Risk Surveillance for Breast Cancer.
    • Christopher Flowers.
    • FORCE. Be Empowered Webinars. 2012 Feb 22.
    • Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes.
    • Lim AW, Mesher D, Gentry-Maharaj A, Balogun N, Jacobs I, Menon U, Sasieni P.
    • J Natl Cancer Inst. 2012 Jan 18;104(2):114-24. doi: 10.1093/jnci/djr486. Epub 2012 Jan 13.

    Comment/Editorial:

    Finding ovarian cancer.

    Press: Symptom Screening Indexes Do Not Detect Early Ovarian Cancer. (Medscape Oncology)

    • Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.
    • Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.
    • Integrating breast cancer genetics into clinical practice.
    • Mukherjee A, Rakha EA.
    • Womens Health (Lond Engl). 2012 Jan;8(1):99-112. doi: 10.2217/whe.11.81.
    • Review